SECOND MALIGNANCIES IN 559 PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE: DATA FROM THE GIMEMA CML WORKING PARTY

被引：0
|
作者：
Gugliotta, G. [1 ]
Castagnetti, F. [1 ]
Palandri, F. [1 ]
Breccia, M. [2 ]
Radaelli, F. [3 ]
Capucci, A. [4 ]
Cavazzini, F. [5 ]
Ferrero, D. [6 ]
Stagno, F. [7 ]
Gherlinzoni, F. [4 ]
Di Lorenzo, R. [4 ]
Leoni, P. [8 ]
Cambrin, G. Rege [6 ]
Ferrara, F. [4 ]
Alimena, G. [2 ]
Martinelli, G. [1 ]
Pane, F. [9 ]
Saglio, G. [6 ]
Baccarani, M. [1 ]
Rosti, G. [1 ]
机构：
[1] Univ Bologna, S Orsola M Malpighi Hosp, Inst L & Seragnoli, Bologna, Italy
[2] Univ Roma La Sapienza, Dept Haematol, Rome, Italy
[3] Univ Milan, Dept Haematol, Milan, Italy
[4] Haematol Unit, Brescia, Italy
[5] Univ Ferrara, Dept Haematol, I-44100 Ferrara, Italy
[6] Univ Turin, Dept Haematol, Turin, Italy
[7] Univ Catania, Dept Haematol, Catania, Italy
[8] Univ Ancona, Dept Haematol, Ancona, Italy
[9] Univ Naples Federico II, Dept Haematol, Naples, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0805
引用
收藏
页码：337 / 337
页数：1
相关论文
共 50 条
  • [31] Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    F Castagnetti
    G Gugliotta
    M Breccia
    F Stagno
    A Iurlo
    F Albano
    E Abruzzese
    B Martino
    L Levato
    T Intermesoli
    P Pregno
    G Rossi
    F Gherlinzoni
    P Leoni
    F Cavazzini
    C Venturi
    S Soverini
    N Testoni
    G Alimena
    M Cavo
    G Martinelli
    F Pane
    G Saglio
    G Rosti
    M Baccarani
    Leukemia, 2015, 29 : 1823 - 1831
  • [32] Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction
    Tong, Weigang
    Kantarjian, Hagop
    O'Brien, Susan
    Faderl, Stefan
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Burton, Elizabeth
    Rios, Mary Beth
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 741 - 741
  • [33] Role of Erythropoietin in the Late Anemia of Patients with Chronic Myeloid Leukemia Treated Frontline with Imatinib
    Cesini, Laura
    Frieri, Camilla
    Barate, Claudia
    Sora, Federica
    Cerrano, Marco
    Cagnetta, Antonia
    Aprile, Lara
    Sgherza, Nicola
    Trawinska, Malgorzata Monika
    Gozzini, Antonella
    Carmosino, Ida
    Ricci, Federica
    Bocchia, Monica
    Bergamaschi, Micaela
    Aguzzi, Chiara
    Sica, Simona
    Galimberti, Sara
    Breccia, Massimo
    Pane, Fabrizio
    Luciano, Luigiana
    Latagliata, Roberto
    BLOOD, 2017, 130
  • [34] No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)
    Iglesias, Lilian
    Mukherjee, Sudipto
    Nazha, Aziz
    Advani, Anjali S.
    Gerds, Aaron T.
    Carraway, Hetty E.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Majhail, Navneet S.
    Sekeres, Mikkael A.
    BLOOD, 2017, 130
  • [35] SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Enrico, A.
    Pavlovsky, C.
    Mariano, R.
    Moiraghi, B.
    Bendek, G.
    Milone, J.
    HAEMATOLOGICA, 2013, 98 : 551 - 551
  • [36] Deletions of the derivative chromosome 9 do not influence response to imatinib of early chronic phase chronic myeloid leukemia patients (A GIMEMA working party analysis).
    Castagnetti, Fausto
    Marzocchi, Giulia
    Luatti, Simona
    Buontempo, Francesca
    Baldazzi, Carmen
    Palandri, Francesca
    Giannoulia, Panagiota
    Amabile, Marilina
    Iacobucci, Ilaria
    Mancini, Marco
    Giussani, Ursula
    Specchia, Giorgina
    Cuneo, Antonio
    Gugliano, Emilia
    Kerim, Simonetta
    Modaferri, Bruno
    Abruzzese, Elisabetta
    Martinelli, Giovanni
    Testoni, Nicoletta
    Rosti, Gianantonio
    Baccarani, Michele
    BLOOD, 2006, 108 (11) : 599A - 599A
  • [37] Monitoring of minimal residual disease of patients with chronic myeloid leukemia (CML) treated with imatinib
    Herrera, P.
    Calbacho, M.
    Ramos, M. L.
    Heras, C.
    Ferro, M. T.
    Cabello, P.
    Villalon, L.
    Lopez, J.
    Odriozola, J.
    CHROMOSOME RESEARCH, 2005, 13 : 194 - 194
  • [38] Deletions of the derivative chromosome 9 do not influence response to imatinib in early chronic phase chronic myeloid leukemia patients (A Gimema Working Party Analysis)
    Castagnetti, F.
    Palandri, F.
    Marzocchi, G.
    Luatti, S.
    Testoni, N.
    Amabile, M.
    Soverini, S.
    Kerim, S.
    Giugliano, E.
    Specchia, G.
    Cuneo, A.
    Martinelli, G.
    Alimena, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 338 - 339
  • [39] HYPOPHOSPHATEMIA AS A PREDICTOR OF RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH IMATINIB
    Garrido, T.
    Amorim, M.
    Gomes, P.
    Trigo, F.
    Guimaraes, J.
    HAEMATOLOGICA, 2014, 99 : 339 - 339
  • [40] LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FRONTLINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    Gozzini, A.
    Stagno, F.
    Rege-Cambrin, G.
    Carella, A. M.
    Luciano, L.
    Abruzzese, E.
    Martino, B.
    Usala, E.
    Rossi, G.
    Bocchia, M.
    Cavazzini, F.
    Tiribelli, M.
    Luatti, S.
    Venturi, C.
    Soverini, S.
    Cavo, M.
    Specchia, G.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Rosti, G.
    Baccarani, M.
    HAEMATOLOGICA, 2015, 100 : 131 - 131
12345